DNA methylation in pre-diagnostic serum samples of breast cancer cases: Results of a nested case-control study

Cancer Epidemiology

Volumn 34, Issue 6, 2010, Pages 717-723

  Brooks, Jennifer D ^a,b   Cairns, Paul ^c   Shore, Roy E ^a,d   Klein, Catherine B ^a   Wirgin, Isaac ^a   Afanasyeva, Yelena ^a   Zeleniuch Jacquotte, Anne ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

Author keywords

Breast cancer; DNA methylation; Early detection; QMSP; Serum

Indexed keywords

APC PROTEIN; GLUTATHIONE TRANSFERASE P1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST DISEASE; CANCER DIAGNOSIS; CANCER GENETICS; CASE CONTROL STUDY; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; DNA METHYLATION; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 78650179036     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.05.006     Document Type: Article

References (50)

1. Etzioni R., Urban N., Ramsey S., McIntosh M., Schwartz S., Reid B., et al. The case for early detection. Nat Rev Cancer 2003, 3(4):243-252.
2. Weir H.K., Thun M.J., Hankey B.F., Ries L.A.G., Howe H.L., Wingo P.A., et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003, 95(17):1276-1299.
3. Cancer Trends Progress Report-2007 Update. National Cancer Institute, NIH, DHHS, Bethesda, MD. (December 2007). http://progresspreport.cancer.gov/.
4. Berg W.A., Gutierrez L., NessAiver M.S., Carter W.B., Bhargavan M., Lewis R.S., et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 2004, 233(3):830-849.
5. Evans A. Hormone replacement therapy and mammographic screening. Clin Radiol 2002, 57(7):563-564.
6. Zhi H., Ou B., Luo B.-M., Feng X., Wen Y.-L., Yang H.-Y. Comparison of ultrasound elastography, mammography, and sonography in the diagnosis of solid breast lesions. J Ultrasound Med 2007, 26(6):807-815.
7. Maskarinec G., Meng L., Ursin G. Ethnic differences in mammographic densities. Int J Epidemiol 2001, 30(5):959-965.
8. Levenson V.V. Biomarkers for early detection of breast cancer: what, when, and where?. Biochim Biophys Acta (BBA) - Gen Subj 2007, 1770(6):847-856.
9. Lopez J.K., Bassett L.W. Invasive lobular carcinoma of the breast: spectrum of mammographic, US, and MR imaging findings. Radiographics 2009, 29(1):165-176.
10. Elmore J.G., Barton M.B., Moceri V.M., Polk S., Arena P.J., Fletcher S.W. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998, 338(16):1089-1096.
11. Ernster V., Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relationto mammography: a dilemma. J Natl Cancer Inst Monogr 1997, 22:151-156.
12. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128(4):683-692.
13. Fackler M., McVeigh M., Evron E., Garrett E., Mehrotra J., Polyak K., et al. DNA methylation of RASSF1A, HIN-1, RAR-β, Cyclin D2 and TWIST in in situ and invasive lobular breast carcinoma. Int J Cancer 2003, 107(6):970-975.
14. Fackler M.J., McVeigh M., Mehrotra J., Blum M.A., Lange J., Lapides A., et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 2004, 64(13):4442-4452.
15. Parrella P., Poeta M.L., Gallo A.P., Prencipe M., Scintu M., Apicella A., et al. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 2004, 10(16):5349-5354.
16. Jeronimo C., Costa I., Martins M.C., Monteiro P., Lisboa S., Palmeira C., et al. Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin Cancer Res 2003, 9(9):3413-3417.
17. Tao M., Shields P., Nie J., Millen A., Ambrosone C., Edge S., et al. DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat 2009, 114(3):559-568.
18. Shinozaki M., Hoon D.S.B., Giuliano A.E., Hansen N.M., Wang H.-J., Turner R., et al. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 2005, 11(6):2156-2162.
19. Li S., Rong M., Iacopetta B. DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett 2006, 237(2):272-280.
20. Diehl F., Li M., Dressman D., He Y., Shen D., Szabo S., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005, 102(45):16368-16373.
21. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.-D., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001, 61(4):1659-1665.
22. Hoque M.O., Feng Q., Toure P., Dem A., Critchlow C.W., Hawes S.E., et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 2006, 24(26):4262-4269.
23. Müller H.M., Widschwendter A., Fiegl H., Ivarsson L., Goebel G., Perkmann E., et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 2003, 63(22):7641-7645.
24. Papadopoulou E., Davilas E., Sotiriou V., Georgakopoulos E., Georgakopoulou S., Koliopanos A., et al. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann N Y Acad Sci 2006, 1075(1):235-243.
25. Tan S.-H., Ida H., Lau Q.-C., Goh B.-C., Chieng W.-S., Loh M., et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep 2007, 18(5):1225-1230.
26. Dulaimi E., Hillinck J., de Caceres I.I., Al-Saleem T., Cairns P. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 2004, 10(18):6189-6193.
27. Sharma G., Mirza S., Prasad C.P., Srivastava A., Gupta S.D., Ralhan R. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci 2007, 80(20):1873-1881.
28. Mirza S., Sharma G., Prasad C.P., Parshad R., Srivastava A., Gupta S.D., et al. Promoter hypermethylation of TMS1, BRCA1, ER[alpha] and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci 2007, 81(4):280-287.
29. Shukla S., Mirza S., Sharma G., Parshad R., Gupta S.D., Ralhan R. Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients. Epigenetics 2006, 1(2):88-93.
30. Hu X.-C., Wong I., Chow L. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications. Oncol Rep 2003, 10:1811-1815.
31. Jeronimo C., Monteiro P., Henrique R., Dinis-Ribeiro M., Costa I., Costa V., et al. Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Res Treat 2008, 109(1):27-34.
32. Zeleniuch-Jacquotte A., Shore R., Koenig K., Akhmedkhanov A., Afanasyeva Y., Kato I., et al. Postmenopausal levels of oestrogen, andorgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 2004, 90:153-159.
33. Kato I., Toniolo P., Koenig K.L., Kahn A., Schymura M., Zeleniuch-Jacquotte A. Comparison of active and cancer registry-based follow-up for breast cancer in a prospective cohort study. Am J Epidemiol 1999, 149:372-378.
34. Eads C.A., Lord R.V., Kurumboor S.K., Wickramasinghe K., Skinner M.L., Long T.I., et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000, 60(18):5021-5026.
35. Widschwendter M., Siegmund K.D., Muller H.M., Fiegl H., Marth C., Muller-Holzner E., et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004, 64(11):3807-3813.
36. Schmiemann V., Bocking A., Kazimirek M., Onofre A.S.C., Gabbert H.E., Kappes R., et al. Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study. Clin Cancer Res 2005, 11(21):7728-7734.
37. Toniolo P., Levitz M., Zeleniuch-Jacquotte A., Banerjee S., Koenig K., Shore R., et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995, 87(3):190-197.
38. van Beers E., Joosse S., Lightenberg M., Fles R., Hogervorst F., Verhoef S., et al. A multiplex PCR predictor for aCGH success of FFPE samples. Br J Cancer 2006, 94:333-337.
39. Pepe M.S., Etzioni R., Feng Z., Potter J.D., Thompson M.L., Thornquist M., et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93(14):1054-1061.
40. Pepe M.S. Evaluating technologies for classification and prediction in medicine. Stat Med 2005, 24(24):3687-3696.
41. Yazici H., Terry M.B., Cho Y.H., Senie R.T., Liao Y., Andrulis I., et al. Aberrant methylation of RASSF1A in plasma DNA before breast cancer diagnosis in the breast cancer family registry. Cancer Epidemiol Biomarkers Prev 2009, 18(10):OF1-3.
42. Brooks J., Cairns P., Zeleniuch-Jacquotte A. Promoter methylation and the detection of breast cancer. Cancer Causes Control 2009.
43. Cottrell S.E., Laird P.W. Sensitive detection of DNA methylation. Ann N Y Acad Sci 2003, 983(1):120-130.
44. Wu T.-L., Zhang D., Chia J.-H., Tsao K.-C., Sun C.-F., Wu J.T. Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta 2002, 321(1-2):77-87.
45. Taback B., O'Day S.J., Hoon D.S.B. Quantification of circulating DNA in the plasma and serum of cancer patients. Ann N Y Acad Sci 2004, 1022:17-24. (Circulating Nucleic Acids in Plasma/Serum III and Serum Proteomics).
46. Ogino S., Kawasaki T., Brahmandam M., Cantor M., Kirkner G.J., Spiegelman D., et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (methylight) for quantitative dna methylation analysis. J Mol Diagn 2006, 8(2):209-217.
47. Vasilatos S.N., Broadwater G., Barry W.T., Baker J.C., Lem S., Dietze E.C., et al. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev 2009, 18(3):901-914.
48. Lewis C.M., Cler L.R., Bu D.-W., Zochbauer-Muller S., Milchgrub S., Naftalis E.Z., et al. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res 2005, 11(1):166-172.
49. Fraga M., Agrelo R., Esteller M. Cross-talk between aging and cancer. Ann N Y Acad Sci 2007, 1100:60-74. (Biogerontology Mechanisms and Interventions).
50. Fraga M.F., Ballestar E., Paz M.F., Ropero S., Setien F., Ballestar M.L., et al. From the cover: epigenetic differences arise during the lifetime of monozygotic twins. PNAS 2005, 102(30):10604-10609.